IONS vs INCY โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
INCY Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Incyte Genomics Inc (INCY) driven by superior Valuation, Growth & Margin, Momentum & Technical while IONS counters with relative strength in Options & Structure. Fundamentally, IONS trades at 90.9x Forward P/E with -58.8% operating margin (+54.9% YoY revenue) versus INCY at 14.0x Forward P/E and 32.2% operating margin (+14.0% YoY). In options structure, IONS sits in BREAKDOWN (17th %ile IV; Dealer Gamma Walls on Pro) against INCY sits in CONSOLIDATION (64th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | IONS Revenue | INCY Revenue | IONS Op. Margin | INCY Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $600M | $1.88B | -10.2% | 6.9% | INCY |
| FY2019 | $1.12B | $2.16B | 32.6% | 18.6% | IONS |
| FY2020 | $730M | $2.67B | -23.6% | -9.9% | INCY |
| FY2021 | $810M | $2.99B | -3.7% | 19.6% | INCY |
| FY2022 | $590M | $3.39B | -69.8% | 17.1% | INCY |
| FY2023 | $790M | $3.70B | -44.9% | 16.8% | INCY |
| FY2024 | $710M | $4.24B | -67.4% | 1.4% | INCY |
| FY2025 | $940M | $5.14B | -40.4% | 29.5% | INCY |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | IONS | INCY | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $4.7B | $24.8B | Larger Scale | INCY |
| Trailing P/E Ratio Valuation | 90.9x | 62.1x | Lower Multiple | INCY |
| Forward P/E Ratio Valuation | 90.9x | 14.0x | Lower Multiple | INCY |
| Revenue Growth (YoY) Growth | +54.9% | +14.0% | Higher Growth | IONS |
| Operating Margin (TTM) Profitability | -58.8% | 32.2% | Higher Margin | INCY |
| Net Profit Margin Profitability | -56.9% | 6.7% | Higher Margin | INCY |
| Return on Equity (ROE) Capital Efficiency | -108.0% | 7.8% | Higher ROE | INCY |
| 52-Week Range Position Momentum | 2% ($27โ$87) | 71% ($89โ$133) | Stronger Trend | INCY |
| Beta / 30D Volatility Risk Regime | 0.18ฮฒ ยท 86% Vol | 0.30ฮฒ ยท 35% Vol | Lower Realized Risk | INCY |
| Unified Institutional Score Composite Signal | 63.9 / 100 (BUY) | 61.2 / 100 (BUY) | Higher Composite | IONS |